Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
40.3 (1y: +5%)
Market Cap 34.34 B P/E(ttm) 19.60
Enterprise Value 45.6 B P/B 1.50
TEVJF- OTCPK (USA)
Teva Pharmaceutical Industries Ltd
  • Currently 4.5/5
Business Predictability Rank: 4.5-Star
Back Testing Results:
Average gain of all 4.5-Star stocks: 10.6% per year.
% of Stocks that are in still loss if held for 10yrs: 10%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$40.30
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.196
OTCPK:TEVJF's Cash to Debt is ranked lower than
93% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.28 vs. OTCPK:TEVJF: 0.196 )
OTCPK:TEVJF' s 10-Year Cash to Debt Range
Min: 0.08   Max: 1.03
Current: 0.2
0.08
1.03
Equity to Asset -0.076
OTCPK:TEVJF's Equity to Asset is ranked lower than
93% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.56 vs. OTCPK:TEVJF: -0.076 )
OTCPK:TEVJF' s 10-Year Equity to Asset Range
Min: -0.13   Max: 0.4
Current: -0.08
-0.13
0.4
Interest Coverage 6.2
OTCPK:TEVJF's Interest Coverage is ranked lower than
60% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.90 vs. OTCPK:TEVJF: 6.2 )
OTCPK:TEVJF' s 10-Year Interest Coverage Range
Min: 4   Max: No Debt
Current: 6.2
F-Score: 6
Z-Score: 1.74
M-Score: -3.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 10.90
OTCPK:TEVJF's Operating margin (%) is ranked higher than
62% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.80 vs. OTCPK:TEVJF: 10.90 )
OTCPK:TEVJF' s 10-Year Operating margin (%) Range
Min: 9.5   Max: 26.8
Current: 10.9
9.5
26.8
Net-margin (%) 9.7
OTCPK:TEVJF's Net-margin (%) is ranked higher than
67% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. OTCPK:TEVJF: 9.7 )
OTCPK:TEVJF' s 10-Year Net-margin (%) Range
Min: 5.7   Max: 21.1
Current: 9.7
5.7
21.1
ROE (%) 8.6
OTCPK:TEVJF's ROE (%) is ranked higher than
63% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. OTCPK:TEVJF: 8.6 )
OTCPK:TEVJF' s 10-Year ROE (%) Range
Min: 3.9   Max: 22.4
Current: 8.6
3.9
22.4
ROA (%) 3.9
OTCPK:TEVJF's ROA (%) is ranked higher than
52% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. OTCPK:TEVJF: 3.9 )
OTCPK:TEVJF' s 10-Year ROA (%) Range
Min: 1.9   Max: 11.7
Current: 3.9
1.9
11.7
ROC (Joel Greenblatt) (%) 22.30
OTCPK:TEVJF's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.40 vs. OTCPK:TEVJF: 22.30 )
OTCPK:TEVJF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 15   Max: 47.4
Current: 22.3
15
47.4
Revenue Growth (%) 10.7
OTCPK:TEVJF's Revenue Growth (%) is ranked higher than
77% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. OTCPK:TEVJF: 10.7 )
OTCPK:TEVJF' s 10-Year Revenue Growth (%) Range
Min: 10.4   Max: 17.1
Current: 10.7
10.4
17.1
EBITDA Growth (%) 4.9
OTCPK:TEVJF's EBITDA Growth (%) is ranked higher than
74% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. OTCPK:TEVJF: 4.9 )
OTCPK:TEVJF' s 10-Year EBITDA Growth (%) Range
Min: -3.2   Max: 31.9
Current: 4.9
-3.2
31.9
EPS Growth (%) 0.2
OTCPK:TEVJF's EPS Growth (%) is ranked higher than
70% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. OTCPK:TEVJF: 0.2 )
OTCPK:TEVJF' s 10-Year EPS Growth (%) Range
Min: -16.3   Max: 47.7
Current: 0.2
-16.3
47.7
ยป OTCPK:TEVJF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OTCPK:TEVJF



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/E(ttm) 19.60
TEVJF's P/E(ttm) is ranked lower than
297619% of the 336 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.80 vs. TEVJF: 19.60 )
TEVJF' s 10-Year P/E(ttm) Range
Min: 10.53   Max: 938.25
Current: 19.6
10.53
938.25
P/B 1.50
TEVJF's P/B is ranked lower than
238095% of the 420 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.51 vs. TEVJF: 1.50 )
TEVJF' s 10-Year P/B Range
Min: 1.37   Max: 9.01
Current: 1.5
1.37
9.01
P/S 1.70
TEVJF's P/S is ranked lower than
231481% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. TEVJF: 1.70 )
TEVJF' s 10-Year P/S Range
Min: 1.6   Max: 5.94
Current: 1.7
1.6
5.94
PFCF 8.90
TEVJF's PFCF is ranked lower than
411522% of the 243 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.36 vs. TEVJF: 8.90 )
TEVJF' s 10-Year PFCF Range
Min: 8.45   Max: 203.3
Current: 8.9
8.45
203.3
EV-to-EBIT 21.3
TEVJF's EV-to-EBIT is ranked lower than
273224% of the 366 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.66 vs. TEVJF: 21.3 )
TEVJF' s 10-Year EV-to-EBIT Range
Min: 11.9   Max: 987.7
Current: 21.3
11.9
987.7
PEG 1
TEVJF's PEG is ranked lower than
606060% of the 165 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.01 vs. TEVJF: 1 )
TEVJF' s 10-Year PEG Range
Min: 0.41   Max: 96.43
Current: 1
0.41
96.43
Shiller P/E 15.3
TEVJF's Shiller P/E is ranked lower than
100% of the Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: vs. TEVJF: 15.3 )
TEVJF' s 10-Year Shiller P/E Range
Min: 14.08   Max: 75.19
Current: 15.3
14.08
75.19

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 2.30
TEVJF's Dividend Yield is ranked lower than
442477% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.21 vs. TEVJF: 2.30 )
TEVJF' s 10-Year Dividend Yield Range
Min: 0.12   Max: 2.34
Current: 2.3
0.12
2.34
Dividend Payout 0.3391
TEVJF's Dividend Payout is ranked lower than
534759% of the 187 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.40 vs. TEVJF: 0.3391 )
TEVJF' s 10-Year Dividend Payout Range
Min: 0.05   Max: 0.53
Current: 0.34
0.05
0.53
Dividend growth (3y) 13.6
TEVJF's Dividend growth (3y) is ranked higher than
58% of the 52 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.70 vs. TEVJF: 13.6 )
TEVJF' s 10-Year Dividend growth (3y) Range
Min: 13.6   Max: 56
Current: 13.6
13.6
56
Yield on cost (5-Year) 5.75
TEVJF's Yield on cost (5-Year) is ranked lower than
440528% of the 227 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. TEVJF: 5.75 )
TEVJF' s 10-Year Yield on cost (5-Year) Range
Min: 0.3   Max: 5.85
Current: 5.75
0.3
5.85
Share Buyback Rate 0.6
TEVJF's Share Buyback Rate is ranked lower than
1612902% of the 62 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. TEVJF: 0.6 )
TEVJF' s 10-Year Share Buyback Rate Range
Min: 0.6   Max: -8.1
Current: 0.6

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 5
TEVJF's Price/Net Current Asset Value is ranked lower than
255754% of the 391 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.80 vs. TEVJF: 5 )
TEVJF' s 10-Year Price/Net Current Asset Value Range
Min: 4.7   Max: 13.4
Current: 5
4.7
13.4
Price/DCF (Projected) 0.6
TEVJF's Price/DCF (Projected) is ranked lower than
624999% of the 160 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. TEVJF: 0.6 )
TEVJF' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 3.3
Current: 0.6
0.6
3.3
Price/Median PS Value 0.4
TEVJF's Price/Median PS Value is ranked lower than
243902% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. TEVJF: 0.4 )
TEVJF' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.4
Current: 0.4
0.4
1.4
Price/Peter Lynch Fair Value 1.4
TEVJF's Price/Peter Lynch Fair Value is ranked lower than
1204818% of the 83 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. TEVJF: 1.4 )
TEVJF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.6   Max: 10.2
Current: 1.4
0.6
10.2
Earnings Yield (Greenblatt) 4.70
TEVJF's Earnings Yield (Greenblatt) is ranked lower than
51% of the 361 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. TEVJF: 4.70 )
TEVJF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.4
Current: 4.7
0.1
8.4
Forward Rate of Return (Yacktman) 20.84
TEVJF's Forward Rate of Return (Yacktman) is ranked lower than
704225% of the 142 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.10 vs. TEVJF: 20.84 )
TEVJF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.3   Max: 37.6
Current: 20.84
8.3
37.6

Business Description

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Company Website
Industry: Drug Manufacturers - Specialty & Generic
Compare:
Traded in other countries:TEVA.USA, TEV.Germany
ยป More Articles for OTCPK:TEVJF

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial